An immunologic portrait of cancer

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Ascierto, Maria L ^a,b,c   Giorgi, Valeria De ^a   Liu, Qiuzhen ^a   Bedognetti, Davide ^a,c,d   Spivey, Tara L ^a   Murtas, Daniela ^a   Uccellini, Lorenzo ^a   Ayotte, Ben D ^e   Stroncek, David F ^a   Chouchane, Lotfi ^f   Manjili, Masoud H ^g   Wang, Ena ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c Center of Excellence for Biomedical Research (CEBR)   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e NORTHERN MICHIGAN UNIVERSITY   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; MELANOMA ANTIGEN 3; PEPTIDE VACCINE; TUMOR ANTIGEN;

ADJUVANT THERAPY; CANCER CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; INFECTION; INFLAMMATION; LUNG NON SMALL CELL CANCER; MELANOMA; PROGNOSIS; REVIEW; TUMOR MICROENVIRONMENT; TUMOR REJECTION; GENETICS; IMMUNITY; IMMUNOLOGY; NEOPLASM;

HUMANS; IMMUNITY; NEOPLASMS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 80052083328     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-146     Document Type: Review

References (131)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Bedrick JC, Sabet H, Tran T, Xin Y, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:467-578.
2. Bittner M, Meltzer P, Chen Y, Jiang E, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, et al. Molecular classification of cutaneous malignant melanoma by gene expression: shifting from a countinuous spectrum to distinct biologic entities. Nature 2000, 406:536-840. 10.1038/35020115, 10952317.
3. Perou CM, Sertle T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, al-Katib A, et al. Molecular portraits of human breast tumorurs. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
4. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 2008, 371:771-783. 10.1016/S0140-6736(08)60241-X, 18275997.
5. Disis ML. Immune regulation of cancer. J Clin Oncol 2010, 28:4531-4538. 10.1200/JCO.2009.27.2146, 20516428.
6. Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E. Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma 2007, 48:2403-2411. 10.1080/10428190701665954, 18067016.
7. Ho CC, Liao WY, Wang CY, Lu YH, Huang HY, Chen HY, Chan WK, Chen HW, Yang PC. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 2008, 177:763-770. 10.1164/rccm.200704-641OC, 18096709.
8. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008, 26:2707-2716. 10.1200/JCO.2007.15.6521, 18509183.
9. Immunologic signatures of rejection 2010, New York, NY: Springer.
10. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008, 29:256-262. 10.1016/j.it.2008.03.002, 18457994.
11. Yaqub S, Aandahl EM. Inflammation versus adaptive immunity in cancer pathogenesis. Crit Rev Oncog 2009, 15:43-63.
12. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183. 10.1172/JCI31537, 1857251, 17476347.
13. Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010, 9:555-565. 10.1586/erv.10.55, 20518712.
14. Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010, 22:215-222. 10.1016/j.coi.2010.02.006, 20207124.
15. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899. 10.1016/j.cell.2010.01.025, 2866629, 20303878.
16. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237. 10.1016/j.coi.2010.01.009, 20144856.
17. Lloyd OC. Regression of malignant melanoma as a manifestation of a cellular immunity response. Proc R Soc Med 1969, 62:543-545. 1811110, 5802725.
18. Cochran AJ. Histology and prognosis in malignant melanoma. J Pathol 1969, 97:459-468. 10.1002/path.1710970305, 5360500.
19. Clemente CG, Mihm MCJ, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310. 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5, 8608507.
20. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol 2003, 24:335-342.
21. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002, 62:3581-3586. 2241738, 12097256.
22. Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, Freedman RS, Marincola FM. Melanoma-restricted genes. J Transl Med 2004, 2:34. 10.1186/1479-5876-2-34, 527872, 15488140.
23. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
24. Ascierto ML, Kmieciak M, Idowo MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang X-Y, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2011,
25. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010, 28:367-388. 10.1146/annurev.immunol.021908.132603, 20192808.
26. Gajewski TF. Transcriptional profiling of melanoma as a potential predictive biomarker for response to immunotherapy. Signatures of rejection 2010, 229-238. New York: Springer, Wang E, Marincola FM, First.
27. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009, 69:3077-3085.
28. Gajewski TF, Zha Y, Thurner B, Schuler G. Association of gene expression profile in melanoma and survival to a dentritic cell-based vaccine. J Clin Oncol 2009, 27:A9002.
29. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007, 25(Suppl 2):B61-B71.
30. Louahed J, Grusell O, Gaulis S, Coche T, Eggermont AM, Kruit W, Dreno B, Charion Sileni V, Lehmann F, Brichard VG. Expression of defined genes indentifed by pre-treatment tumor profiling: association with clinical response to GSK MAGE A-3 immunetherapeutic in metastatic melanoma patients. J Clin Oncol 2008, 26:A9045.
31. Sullivan RJ, Hoshida Y, Brunet J, Tahan S, Aldridge J, Kwabi C, Gardiner E, McDermott D, Golub T, Atkins MA. A single center experience with high-dose IL-2 treatment of patients with advanced melanoma and pilot investigation of novel gene expression signature as a predictor of response. J Clin Oncol 2009, 27:A9003.
32. Hamid O, Chasalow SD, Tsuchihashi Z, Alaparthy S, Galbraith S, Berman D. Association of baseline and on-study tumor biopsy markers with clinical activity in patients with advanced melanoma treated with ipilimumab. J Clin Onco 2009, 27:A9008.
33. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24:3164-3171. 10.1200/JCO.2005.05.2498, 16809739.
34. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, Kirkwood JM. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007, 13:1523-1531. 10.1158/1078-0432.CCR-06-1387, 17332298.
35. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488. 10.1038/sj.onc.1203527, 10851046.
36. Levy DE, Gilliland DG. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 2000, 19:2505-2510. 10.1038/sj.onc.1203480, 10851049.
37. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000, 19:2523-2531. 10.1038/sj.onc.1203484, 10851051.
38. Lesinski GB, Trefry J, Brasdovich M, Kondadasula SV, Sackey K, Zimmerer JM, Chaudhury AR, Yu L, Zhang X, Crespin TR, et al. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res 2007, 13:5010-5019. 10.1158/1078-0432.CCR-06-3092, 17785551.
39. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007, 25:869-875. 10.1200/JCO.2006.08.9755, 17327608.
40. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213. 10.1056/NEJMoa020177, 12529460.
41. Leffers N, Fehrmann RS, Gooden MJ, Schulze UR, Ten Hoor KA, Hollema H, Boezen HM, Daemen T, de JS, Nijman HW, et al. Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer 2010, 103:685-692. 10.1038/sj.bjc.6605820, 2938262, 20664601.
42. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, Ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009, 58:449-459. 10.1007/s00262-008-0583-5, 18791714.
43. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102:18538-18543. 10.1073/pnas.0509182102, 1311741, 16344461.
44. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149. 10.1182/blood-2009-03-208249, 2723011, 19470694.
45. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666. 10.1056/NEJMoa051424, 16371631.
46. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P, et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009, 69:2685-2693. 10.1158/0008-5472.CAN-08-2654, 19258510.
47. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors, a prognostic factor that should not be ignored. Oncogene 2009, 29:1093-1102.
48. Pos Z, Galon J. Predictors of favorable outcome in cancer. Immunologic signatures of rejection 2010, 199-210. New York: Springer, Wang E, Marincola FM, 1.
49. Lee WS, Park S, Lee WY, Yun SH, Chun HK. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010, 116:5188-5199. 10.1002/cncr.25293, 20665489.
50. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58:3491-3494.
51. Oberg A, Samii S, Stenling R, Lindmark G. Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis 2002, 17:25-29. 10.1007/s003840100337, 12018450.
52. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010, 33:435-441. 10.1097/CJI.0b013e3181d32f01, 20386463.
53. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011, 71:1263-1271. 10.1158/0008-5472.CAN-10-2907, 21303976.
54. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, rb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28:105-113. 10.1200/JCO.2009.23.7370, 19917869.
55. Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG. Immune signatures predict prognosis in localized cancer. Cancer Invest 2010, 28:765-773. 10.3109/07357900903095755, 20569070.
56. Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, Yfantis HG, Tsai YC, Williams EH, Lee DH, Stephens RM, et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS ONE 2009, 4:e4531. 10.1371/journal.pone.0004531, 2638012, 19225562.
57. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1:203-209. 10.1016/S1535-6108(02)00030-2, 12086878.
58. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008, 68:927-936. 10.1158/0008-5472.CAN-07-2608, 18245496.
59. Foye A, Febbo PG. Cancer gene profiling in prostate cancer. Methods Mol Biol 2010, 576:293-326.
60. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004, 113:913-923. 362118, 15067324.
61. Monsurro' V, Beghelli S, Wang R, Barbi S, Coin S, Di Pasquale G, Bersani S, Castellucci M, Sorio C, Eleuteri S, et al. Anti-viral status segregates two pancreatic adenocarcinoma molecular phenotypes with potential relevance for adenoviral gene therapy. J Transl Med 2010, 8:10. 10.1186/1479-5876-8-10, 2845551, 20113473.
62. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de CL, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008, 26:4410-4417. 10.1200/JCO.2007.15.0284, 18802153.
63. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008, 113:1387-1395. 10.1002/cncr.23712, 18671239.
64. Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 2008, 179:61-66.
65. Shibuya TY, Nugyen N, McLaren CE, Li KT, Wei WZ, Kim S, Yoo GH, Rogowski A, Ensley J, Sakr W. Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res 2002, 8:745-751.
66. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay NH, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006, 12:465-472. 10.1158/1078-0432.CCR-05-1886, 16428488.
67. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007, 104:3967-3972. 10.1073/pnas.0611618104, 1820692, 17360461.
68. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006, 12:3355-3360. 10.1158/1078-0432.CCR-05-2434, 16740757.
69. Wenzel J, Tomiuk S, Zahn S, Kusters D, Vahsen A, Wiechert A, Mikus S, Birth M, Scheler M, von BD, et al. Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. Int J Cancer 2008, 123:2605-2615. 10.1002/ijc.23799, 18770863.
70. Kandalaft LE, Coukos G. The microenvironment of ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Signatures of rejection 2010, 211-228. Ney York: Springer, Wang E, Marincola FM, First.
71. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007, 104:3360-3365. 10.1073/pnas.0611533104, 1805580, 17360651.
72. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008, 108:415-420. 10.1016/j.ygyno.2007.10.016, 18037158.
73. Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol 2008, 109:215-219. 10.1016/j.ygyno.2008.01.010, 18314181.
74. Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009, 115:2891-2902. 10.1002/cncr.24317, 2754811, 19472394.
75. Clarke B, Tinker AV, Lee CH, Subramanian S, Van de RM, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009, 22:393-402. 10.1038/modpathol.2008.191, 19060844.
76. Stumpf M, Hasenburg A, Riener MO, Jutting U, Wang C, Shen Y, Orlowska-Volk M, Fisch P, Wang Z, Gitsch G, et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 2009, 101:1513-1521. 10.1038/sj.bjc.6605274, 2778517, 19861998.
77. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009, 4:e6412. 10.1371/journal.pone.0006412, 2712762, 19641607.
78. Blegen H, Einhorn N, Sjovall K, Roschke A, Ghadimi BM, McShane LM, Nilsson B, Shah K, Ried T, Auer G. Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. Int J Gynecol Cancer 2000, 10:477-487. 10.1046/j.1525-1438.2000.00077.x, 11240718.
79. Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 2007, 37:675-685. 10.1002/eji.200636639, 17304628.
80. Kmieciak M, Payne KK, Idowu MO, Grimes MM, Graham L, Ascierto ML, Wang E, Wang XY, Bear HD, Manjili MH. Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. J Transl Med 2011, 9:35. 10.1186/1479-5876-9-35, 3076247, 21453513.
81. Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 2005, 446:10-14. 10.1007/s00428-004-1143-9, 15660281.
82. Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, von Knebel DM, Kloor M. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 2005, 92:1746-1753. 10.1038/sj.bjc.6602534, 2362037, 15856045.
83. Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996, 174:116-128. 10.1006/cimm.1996.0301, 8954611.
84. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:659-660. 10.1038/44309, 10537102.
85. Wolf AM, Rumpold H, Reimer D, Marth C, Zeimet AG, Wolf D. High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer. Gynecol Oncol 2010, 118:244-250. 10.1016/j.ygyno.2010.05.024, 20603238.
86. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27:186-192. 10.1200/JCO.2008.18.7229, 19064967.
87. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L, Tornillo L. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010, 126:2635-2643.
88. Zlobec I, Karamitopoulou E, Terracciano L, Piscuoglio S, Iezzi G, Muraro MG, Spagnoli G, Baker K, Tzankov A, Lugli A. TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS ONE 2010, 5:e14282. 10.1371/journal.pone.0014282, 3003488, 21179245.
89. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127. 10.1056/NEJMoa1012863, 21631324.
90. Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wieczorek G, Olek S, Dietmaier W, Andreesen R, Edinger M. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 2009, 39:1088-1097. 10.1002/eji.200838904, 19283780.
91. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van LM, Buckner JH, Ziegler SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J Clin Invest 2003, 112:1437-1443. 228469, 14597769.
92. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, Pratap S, Toms C, Fox BC, Cerundolo V, et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005, 35:1681-1691. 10.1002/eji.200526189, 15902688.
93. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129:1275-1286. 10.1016/j.cell.2007.04.034, 1974845, 17570480.
94. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009, 16:336-346. 10.1016/j.ccr.2009.08.016, 2758294, 19800578.
95. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, Barda AK, Gourgoulianis KI, Germenis AE. Foxp3 expression in human cancer cells. J Transl Med 2008, 6:19. 10.1186/1479-5876-6-19, 2386447, 18430198.
96. Wang Y, Liu DP, Chen PP, Koeffler HP, Tong XJ, Xie D. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res 2007, 67:2535-2543. 10.1158/0008-5472.CAN-06-3530, 17363571.
97. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, Coudert B, Martin F, Bizollon MH, Vanoli A, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011, 224:389-400. 10.1002/path.2866, 21437909.
98. 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der KK, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
99. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29:1949-1955. 10.1200/JCO.2010.30.5037, 21483002.
100. Giltnane JM, Rimm DL. Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 2004, 1:104-111. 10.1038/ncponc0046, 16264828.
101. Hassan S, Ferrario C, Mamo A, Basik M. Tissue microarrays: emerging standard for biomarker validation. Curr Opin Biotechnol 2008, 19:19-25. 10.1016/j.copbio.2007.10.009, 18053705.
102. Zeimet AG, Reimer D, Wolf D, Fiegl H, Concin N, Wiedemair A, Wolf AM, Rumpold H, Muller-Holzner E, Marth C. Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. Int J Cancer 2009, 124:2353-2360. 10.1002/ijc.24214, 19170204.
103. Selleri S, Deola S, Pos Z, Jin P, Worschech A, Slezak S, Rumio C, Panelli MC, Maric D, Stroncek DF, et al. GM-CSF/IL-3/IL-5 receptor common B chain (CD131) as a biomarker of antigen-stimulated CD8+ T cells. J Transl Med 2008, 6:17. 10.1186/1479-5876-6-17, 2330025, 18412971.
104. Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst 2004, 96:1331-1342. 10.1093/jnci/djh252, 15339971.
105. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949. 10.1038/nm1093, 15322536.
106. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O'Brien-Jenkins A, Gimotty PA, Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008, 14:28-36. 10.1038/nm1699, 18157142.
107. Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 2009, 15:4521-4528. 10.1158/1078-0432.CCR-08-0543, 2896814, 19567593.
108. Manjili MH. Revisiting cancer immunoediting by understanding cancer immune complexity. J Pathol 2011, 224:5-9. 10.1002/path.2865, 21480229.
109. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2010,
110. Suk K, Kim YH, Chang I, Kim JY, Choi YH, Lee KY, Lee MS. IFNalpha sensitizes ME-180 human cervical cancer cells to TNFalpha-induced apoptosis by inhibiting cytoprotective NF-kappaB activation. FEBS Lett 2001, 495:66-70. 10.1016/S0014-5793(01)02335-3, 11322949.
111. Suk K, Chang I, Kim YH, Kim S, Kim JY, Kim H, Lee MS. Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. J Biol Chem 2001, 276:13153-13159. 10.1074/jbc.M007646200, 11278357.
112. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008, 26:535-584. 10.1146/annurev.immunol.26.021607.090400, 18303999.
113. Lee JH, Chun T, Park SY, Rho SB. Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs. Biochim Biophys Acta 2008, 1783:1654-1662. 10.1016/j.bbamcr.2008.04.006, 18472010.
114. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73. 10.1038/nri2216, 18097448.
115. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54. 10.1038/nm976, 14702634.
116. Jin P, Marincola FM, Wang E. Cytokine polymorphism and its possible impact on cancer. Immunol Res 2004,
117. Hancock WW, Wang L, Ye Q, Han R, Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003, 15:479-486. 10.1016/S0952-7915(03)00103-1, 14499253.
118. Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, et al. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 2008, 14:7667-7673. 10.1158/1078-0432.CCR-08-0479, 3000165, 19047092.
119. Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Doppler W, Daxenbichler G. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004, 191:1598-1605. 10.1016/j.ajog.2004.05.007, 15547530.
120. Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008, 33:122-131. 10.1016/j.tibs.2007.12.002, 18291658.
121. Ueda Y, Richmond A. NF-kappaB activation in melanoma. Pigment Cell Res 2006, 19:112-124. 10.1111/j.1600-0749.2006.00304.x, 2668252, 16524427.
122. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010, 14:45-55. 10.1517/14728220903431069, 3043547, 20001209.
123. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 2010, 336:25-37. 10.1007/s11010-009-0267-2, 3148942, 19823771.
124. Escalante CR, Yie J, Thanos D, Aggarwal AK. Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. Nature 1998, 391:103-106. 10.1038/34224, 9422515.
125. Paun A, Pitha PM. The IRF family, revisited. Biochimie 2007, 89:744-753. 10.1016/j.biochi.2007.01.014, 2139905, 17399883.
126. Shultz DB, Rani MR, Fuller JD, Ransohoff RM, Stark GR. Roles of IKK-beta, IRF1, and p65 in the activation of chemokine genes by interferon-gamma. J Interferon Cytokine Res 2009, 29:817-824. 10.1089/jir.2009.0034, 2956658, 19929594.
127. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007, 4:e176. 10.1371/journal.pmed.0040176, 1865558, 17488182.
128. Critchley-Thorne RJ, Simons D, Yan N, Miyahira A, Dirbas F, Johnson D, Swetter S, Carlson R, Fisher G, Koong A, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 2009, 106:9010-9015. 10.1073/pnas.0901329106, 2690021, 19451644.
129. Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Anichini A. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res 2009, 15:4085-4094. 10.1158/1078-0432.CCR-08-3323, 19509154.
130. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Bruneval P, Zatloukal K, et al. The in situ cytotoxic and memory T cells predict outcome in early-stage colerectal cancer patients. J Clin Oncol 2009,
131. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001, 61:3932-3936.